MedTrace Logo

Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects

NCT01068756 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2016-10-17

No results posted yet for this study

Summary

The purpose of the study is to assess the effects of rifampin on the pharmacokinetics of dapagliflozin

Conditions

Interventions

DRUG

Dapagliflozin

Tablets, Oral, 10 mg, 2 single oral 10 mg doses, 2 days

DRUG

Rifampin

Capsules, Oral, 600 mg, Once daily on days 4 to 11, 8 days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01068756 on ClinicalTrials.gov